--- title: How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust description: Discover our e-DICT™ technology, Acclinate’s engagement intelligence engine that uses real community insight and adaptive outreach to improve recruitment, retention, and trust. image: https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Community](https://blog.acclinate.com/topic/community) [Affective Trust](https://blog.acclinate.com/topic/affective-trust) [e-DICT™](https://blog.acclinate.com/topic/e-dict) # How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust Discover our e-DICT™ technology, Acclinate’s engagement intelligence engine that uses real community insight and adaptive outreach to improve recruitment, retention, and trust. ![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Acclinate](https://blog.acclinate.com/hubfs/69b96486c4b036c19f462c19_acclinate-logo.png) [Acclinate](https://blog.acclinate.com/author/acclinate) Acclinate turns trust and data into better representation. Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [**](https://twitter.com/home?status=https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust&title=How%20Acclinate’s%20e-DICT™%20Technology%20Builds%20Real-Time%20Community%20Trust) Stay up to date Get news directly in your inbox ### Key Takeaways and Learnings - e-DICT™ is Acclinate’s proprietary engagement intelligence engine, tracking deep community health insights in real time. - It surfaces real engagement signals, enabling better sponsor decision-making. - Empowered with real-time insights, clinical outreach strategies can adapt as communities respond. - Sponsors can maximize recruitment and retention with advanced, timely engagement metrics. - [Learn more about our e-DICT™ technology.](https://edictv2.acclinate.com/welcome) Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical context, access barriers, and trust built over time. Yet many engagement strategies still rely on static demographic filters and generic, tired messaging that overlook how communities *actually* interact with healthcare systems. We developed [e-DICT™ technology](https://edictv2.acclinate.com/welcome) to address this disconnect. As Acclinate’s proprietary engine for engagement-driven, intelligent trend monitoring, e-DICT™ supports outreach strategies that adapt based on real community behavior and insight. Instead of guessing what might resonate, organizations can respond to what people are already expressing through their engagement. And this shift is helping accelerate access to high-value clinical research opportunities for underrepresented communities across the US. ## What Is e-DICT™ Technology? e-DICT™ is Acclinate’s engagement intelligence engine designed to guide how clinical research organizations identify, reach, and [connect with underrepresented populations](https://blog.acclinate.com/designing-research-for-underrepresented-patient-populations). It supports smarter decision-making by incorporating ongoing engagement data rather than relying solely on static demographic indicators. At its core, the clinical research analytics platform helps teams answer practical questions that traditional targeting tools struggle with: - Who is engaging right now? - What topics are generating interest or hesitation? - Where does trust appear to be strengthening—or breaking down? By grounding outreach decisions in real engagement signals, e-DICT™ helps organizations align strategy with reality. [![Download Now – Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-188916301454.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLcUPV%2BRxdB4tfz7Y0MsrYjILaX%2BwaD41yEXM3WwXYxTrR2bFsMxM9pmL5zP7F29HeoymCoT%2FuBPfPzxRXiHvODz3X9A1uOYvzrKI3rfQLVzvhl2sFkIL5qU1SeXYnxF5Fg175QNk3gxfTJJbUaTBRQUv8NrbnMWzMgD7JXQRdb78f%2FJEnz87jR04yfXC1eMNPZGYiJSndx4IVVNyA3RAy%2Ba%2FgKhw5Gm6jXJz89uB%2FyxhoyVOVoCRT6MuhN9q9vrw%3D%3D&webInteractiveContentId=188916301454&portalId=19943632) ## Why Traditional Clinical Trial Participant Targeting Falls Short Many outreach models treat engagement as a moment rather than a process. Lists are built, messages are sent, and results are measured primarily by short-term response rates. This approach often overlooks the social and cultural factors that influence whether people feel comfortable participating at all. And the results of this classic method have been underwhelming. In a [large analysis of U.S. trials](https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00069-2/fulltext), the median enrollment was about 80% White, while Black and Hispanic/Latino participants were often at or below 10%, far below their disease burden in many conditions. Why the gap? It’s complex, but one major factor is a failure of engagement despite well-intentioned outreach. Communities that have experienced inconsistent messaging, unclear communication, or limited follow-through are less likely to respond to generic pitches—even when opportunities are relevant. e-DICT™ was designed with this context in mind. It recognizes that engagement builds gradually and that responsiveness matters as much as reach. ## How e-DICT™ Supports Smarter Engagement e-DICT™ brings together multiple sources of insight to inform engagement strategy, including: - Community feedback gathered through sustained participation. - Behavioral patterns that indicate interest, readiness, or hesitation. - Contextual signals that shape how messages are interpreted. These insights go beyond demographics offered by static clinical trial technology to enable outreach strategies to evolve as engagement evolves. Messaging can be refined based on what communities respond to. Channels can shift as preferences become clearer. Timing can improve as readiness signals emerge. Instead of locking strategies before understanding community sentiment, e-DICT™ technology supports continuous adjustment informed by lived engagement. [Learn more about our real-world results with our case studies.](https://www.acclinate.com/resources) ## Building Trust Through Relevance and Responsiveness Trust grows when people feel understood and respected. e-DICT™ helps sponsors in this area by helping engagement teams align outreach with community priorities, communication preferences, and cultural context. Rather than increasing message volume, e-DICT™ helps organizations focus attention where meaningful engagement is already developing. The clinical research analytics platform leverages this approach to help sponsors reduce friction and reinforce credibility, especially among populations that have valid reasons to approach research cautiously. When outreach reflects awareness of prior engagement, it signals that listening is happening alongside communication. ## Supporting Retention and Long-Term Participation e-DICT™ also supports long-term community relationships beyond individual studies. Because it is grounded in ongoing engagement data, insight accumulates rather than resetting with each new initiative. This long-range view supports: - More informed planning for future studies. - Deeper local partnerships. - Greater continuity across programs. Organizations benefit from trust that compounds over time rather than starting from scratch with every outreach effort. Retention depends on consistency and clarity. Participants are more likely to stay engaged when communication feels relevant and responsive throughout a study. e-DICT™ supports retention by helping teams maintain alignment as engagement continues. Messaging can adapt as participant needs change, and outreach remains grounded in demonstrated preferences. This continuity helps reduce drop-off and strengthens the overall study experience. ## Long-Term Value of e-DICT™ Technology Since e-DICT™ leverages real engagement, its value increases with use. Each interaction adds context that informs future decisions, creating a feedback loop grounded in lived community experience. This differentiator is what supports research programs that are more adaptive, more respectful, and more aligned with the communities they aim to serve. Ready to learn more about e-DICT™? [Schedule a 1:1 with our team](https://info.acclinate.com/get-in-touch?hsCtaTracking=041ba01b-d386-494a-a484-da34cb04d7b5%7Ccb8ce007-b832-447c-bdca-78c8ed90b5c5). ## Frequently Asked Questions: e-DICT™ Technology **What is e-DICT™ technology?** e-DICT™ is Acclinate’s proprietary engine for engagement-driven, intelligent community targeting. **How does e-DICT™ differ from demographic targeting tools?** It incorporates engagement behavior and community insight rather than relying only on static demographics. **Is e-DICT™ used only for recruitment?** No. It supports engagement across recruitment, retention, and long-term community relationships. **Can e-DICT™ scale across regions?** Yes, while maintaining cultural and contextual relevance. **Does e-DICT™ replace community engagement teams?** No. It supports teams by informing strategy and improving responsiveness. No technology can replace authentic, human connection. [![Before You Recruit: The Ultimate Guide to Advancing Health Equity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/77a48b61-8ce6-44a3-b69b-3d080ed93db6.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/77a48b61-8ce6-44a3-b69b-3d080ed93db6) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Acclinate", "url" : "https://blog.acclinate.com/author/acclinate" }, "dateModified" : "2026-04-28T18:12:05.912Z", "datePublished" : "2026-02-09T15:30:21.000Z", "headline" : "How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust", "image" : [ "https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ``` ```json { "@context" : "https://schema.org", "@type" : "FAQPage", "mainEntity" : [ { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "e-DICT™ is Acclinate’s proprietary engine for engagement-driven, intelligent community targeting." }, "name" : "What is e-DICT™ technology?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "It incorporates engagement behavior and community insight rather than relying only on static demographics." }, "name" : "How does e-DICT™ differ from demographic targeting tools?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "No. It supports engagement across recruitment, retention, and long-term community relationships." }, "name" : "Is e-DICT™ used only for recruitment?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Yes, while maintaining cultural and contextual relevance." }, "name" : "Can e-DICT™ scale across regions?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "No. It supports teams by informing strategy and improving responsiveness. No technology can replace authentic, human connection." }, "name" : "Does e-DICT™ replace community engagement teams?" } ] } ```